EGFR/CDK2-IN-2

Cat. No.:	HY-156114
Molecular Formula:	$C_{49}H_{32}N_{12}O_2S_2$
Molecular Weight:	884.99
Target:	EGFR; CDK
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	EGFR/CDK2-IN-2 (compound 6a) is a dual inhibitor of EGFR and CDK-2 with IC_{50}s of 19.6 and 87.9 nM, respectively. EGFR/CDK2-IN-2 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-2 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC_{50} of 0.39 μM[1].
IC_{50} & Target	IC50: 19.6 (EGFR), 87.9 nM (CDK-2)[1]

REFERENCES

[1]. Salem M E, et al. Synthesis and Anti-Breast Cancer Potency of Mono-and Bis-(pyrazolyl [1, 2, 4] triazolo [3, 4-b][1, 3, 4] thiadiazine) Derivatives as EGFR/CDK-2 Target Inhibitors[J]. ACS Omega, 2023.. . .

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA